This is information contained within SLA releases to the...

This is information contained within SLA releases to the ASX!!

Ropren® registered as pharmaceutical, price set at USD 1,125 for a three month course, and
first orders received.

40-50 hospitals and medical centres Moscow and St Petersburg, plus ~100 government funded pharmacies in Moscow, have had pre-launch contact regarding Ropren®. (not only the nine confirmed hospitals!)

Take up will not be uniform. But if 30 hospitals and medical centres in these two cities each take just 80 courses per month, the Tomsk facility will be “sold out” at
current levels of production.

Mr Pellegrino has signed off on a production plan at the Tomsk facility which is on track and already producing 15kg of Bioeffective® R per month at purity sufficient for pharmaceutical production.

At current levels being produced being 3000 courses per month and leaving it at this figure only, SLA revenue if sold only to Russia would be US 40.5 million dollars annually! Cost would have to be taken out.

Read it! It's in black and white!

When the new factory produces:
Assuming the US $1125 figure remains intact, and again Russian sales only, 200kg per month will create 40000 courses!

This equals 45 million dollars US a month or 540 million dollars a year!! The this is not a financial forecast submission suggests profit after all things considered of approximately US 160 million give or take 10 million dollars!

Now what sort of Market Cap and therefore price should we expect of a stock earning this figure in profit!!

Do the usual research as it is in the ASX releases for all to see!!